Therapeutic vitamin d conjugates
US11116816B2 · kind B2 · utility
2Cited by
105References
66Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 29, 2019 |
| Grant date | Sep 14, 2021 |
| Priority date | — |
| Expiry date | Jan 29, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/60
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.